Renal Cancer

**Localized**
- T1b or greater (has not spread beyond the kidney)
  - IRB#16576 Atezolizumab vs placebo as adjuvant therapy following nephrectomy
  - IRB#18121 Nivolumab Combined with Cabozantinib versus Sunitinib

**Metastatic/locally advanced T1b or greater (has not spread beyond the kidney)**
- Clear Cell
  - No Prior Systemic Therapy
    - IRB#16576 Atezolizumab vs placebo as adjuvant therapy following nephrectomy
  - Matustectomy Candidate
  - Prior Systemic Therapy
    - IRB#16576 Atezolizumab vs placebo as adjuvant therapy following nephrectomy
    - No prior VEGF. Up to 1 prior cytokine or immune checkpoint inhibitor
    - IRB#19283 Xynomic Pazopanib +/- Abexinostate in Patients with locally advanced or Metastatic RCC

**Non-Clear Cell**
- Papillary Renal Carcinoma
  - IRB#16085 S1500 – Cabozantinib, Crizotinib, Savolitinib and sunitinib

**Prior Systemic Therapy**
- IRB#11804 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) + Pembro

**Progression on anti-PD-1/PD-L1 mAb monotherapy or in combo w/ other therapies**
- IRB#17027 A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology

**Key**
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php